
A tweak in timing may make an immune-system therapy much more effective for patients undergoing surgery for advanced melanoma, a new clinical trial has found. Researchers showed that giving the therapy — a drug called Keytruda (pembrolizumab) — both before and after surgery slashed the risk of a melanoma recurrence over the next two years.… read on > read on >